Toyama T, Uno H, Yamashita K, Kubuki Y, Suzuki M, Maeda K, Matsuoka H, Tsubouchi H
Second Dept. of Internal Medicine, Miyazaki Medical School.
Gan To Kagaku Ryoho. 1995 Feb;22(2):227-32.
Twenty-five consecutive patients with myelodysplastic syndrome (MDS) were followed in the Second Department of Internal Medicine, Miyazaki Medical School from 1984 to 1993. The diagnosis of MDS was morphologically based on the criteria of FAB. At the time of diagnosis, 9 patients had refractory anemia (RA), 1 had RA with ring sideroblasts (RARS), 6 had RA with excess blasts (RAEB), 6 had RAEB in transformation (RAEB-t), and 3 had chronic myelomonocytic leukemia (CMMoL). Prognostic factors involved in survival times and progression to leukemia were analyzed in these patients; FAB classification of MDS, age, sex, peripheral blood cell counts, bone marrow examination, karyotype, numbers of blasts. None of these prognostic factors had a significant effect on the prognosis of MDS patients. Study of the therapeutic effects on MDS patients revealed no significant increase of survival time in treated MDS patients compared to non-treated patients. Further, no significant difference in survival time was found between MDS patients treated with or without anticancer drugs. These results indicated that MDS patients were pathologically and therapeutically heterogeneous.
1984年至1993年期间，宫崎医科大学第二内科对25例连续性骨髓增生异常综合征（MDS）患者进行了随访。MDS的诊断在形态学上基于FAB标准。诊断时，9例患者为难治性贫血（RA），1例为伴有环形铁粒幼细胞的RA（RARS），6例为伴有过多原始细胞的RA（RAEB），6例为转化中的RAEB（RAEB-t），3例为慢性粒单核细胞白血病（CMMoL）。对这些患者生存时间和白血病进展相关的预后因素进行了分析；包括MDS的FAB分类、年龄、性别、外周血细胞计数、骨髓检查、核型、原始细胞数量。这些预后因素均未对MDS患者的预后产生显著影响。对MDS患者治疗效果的研究表明，与未治疗的患者相比，接受治疗的MDS患者生存时间未显著延长。此外，接受或未接受抗癌药物治疗 的MDS患者生存时间无显著差异。这些结果表明，MDS患者在病理和治疗方面具有异质性。
